HuMax-EGFr

Status : investigational

Description

HuMax-EGFr™ is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells.

Used

Investigated for use/treatment in head and neck cancer and lung cancer.

Mechanism Of Action

HuMax-EGFr effectively inhibits the growth of tumor cells that express both mutated or normal EGF receptors. This inhibition occurred through different mechanisms of action including direct inhibition of cancer cell growth and an immune cell-mediated killing activity known as antibody dependent cell-mediated cytotoxicity (ADCC).

Chemical Classification

Peptides

Organic Compounds

Organic Acids

Carboxylic Acids and Derivatives

Amino Acids, Peptides, and Analogues

Calculated Property

kind Value Source

Target within organism

  • Epidermal growth factor receptor : in Human